IFF's Scent recovery hinges on a rebuilt R&D engine, a stabilized Fine Fragrance trajectory despite Middle East volatility, and a Consumer Fragrance rebound driven by go-to-market improvements and market-share goals, with Fragrance Ingredients providing near-term momentum. In 2H 2026, Fine Fragrance is expected to post mid-single-digit growth, while Consumer Fragrance normalizes to the low single digits, supported by an enduring 2027 R&D-focused plan.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management directly attributes the turnaround to a sustained R&D rebuild over the last ~2.5 years, including improvements in pipeline quality, perfumer output, and delivery systems/molecules. Specifically, the company says that “2.5 years ago” the R&D pipeline “was not what it should have been,” and that today IFF has “a very strong R&D capability,” “a great pipeline of molecules as well as delivery systems,” and “leading-edge new Fine Fragrances and Consumer Fragrances.” 1
Fine Fragrance performance is described as being affected by Middle East uncertainty, but the team executed well in Q2 and is positioning for improvement as the year progresses. In Q2, Fine Fragrance “finished up slightly positive” even though management had expected growth “down… mid-single digits” going into the quarter. 2
For timing in 2H, management frames a “softer Q3” and “a stronger Q4,” with the second half expected to be “mid-single-digit” growth on a second-half basis. 3
They also explain that a “big comp” exists in Q3: Fine Fragrance grew “20%” year-over-year in Q3 last year, making current growth harder to sustain in Q3 even if the underlying trajectory is improving. 2
On the Consumer Fragrance side, the recovery is framed more around rebuilding R&D and go-to-market execution and driving market share gains, rather than just “one-off” demand relief. Management states that the team has rebuilt “the R&D capability,” refreshed “go-to-market approach with customers,” and is “trying to drive market share gains.” 3
Financially, Consumer Fragrance is guided to be in the “low single-digit range” in the future, with normalization after a strong Q2. 3
While your question is specifically about Scent recovery (Fine/Consumer), IFF also points to Fragrance Ingredients as a major contributor to Scent segment performance and overall recovery momentum. In Q2, the Scent team reports Sales up 8%, with Fragrance Ingredients growing “north of 20%,” driven partly by difficult prior-year comparisons (prior year down “10% or more”). 2
Management also says this Q2 performance included leveraging the synthetics portfolio amid “macro… supply chain disruptions and higher Brent crude prices,” with normalization expected as conditions settle. 2
They further clarify that growth in the second half is forecast to shift “back towards the higher value-added ingredients versus the traditional synthetics” that were a “strong point in Q2.” 2
They also note Fragrance Ingredients should “normalize” going forward and be “slightly under pressure” year-over-year to calibrate. 3
While not a direct “Fine vs Consumer” driver, it affects the environment through which Scent recovery must occur:
The excerpts provide fewer “mechanistic” R&D program details than financial targets/timing, but they do offer clear strategic elements and what management claims will carry forward into 2027.
Management states it has built “a very strong R&D capability” and a “great pipeline of molecules as well as delivery systems,” with “leading-edge” new products for both Fine Fragrances and Consumer Fragrances. 1
This implies that the 2027 support plan is not starting from scratch; it is sustaining the improved capability and pipeline quality that has already been rebuilt. 1
Management explicitly links R&D rebuilding to customer execution and market share: Consumer Fragrance recovery includes rebuilding “R&D capability” and the “go-to-market approach with customers,” with a goal to “drive market share gains.” 3
That suggests the 2027 plan is oriented toward translating R&D output into customer wins and share gains rather than R&D in isolation. 3
For Fragrance Ingredients, management describes a shift to “higher-value natural products” as “underway,” and while it “will take a little bit more time” it is expected that “as we go into next year and the year after, we believe we’ll have a really strong competitive position.” 3
Because Scent segment performance is closely tied to Fragrance Ingredients momentum (including in Q2), this “competitive position” expectation provides one of the clearest indications of how R&D/product strategy is intended to support 2027 outcomes. 32
Management emphasizes that innovation/investment continues to be critical, describing R&D as a key continuing pillar of the transformation and stating “innovation matters” and that the reinvestment “circle” supports better growth and margin expansion (within the Remainco strategy context). 5
While this is broader than Scent-only, it frames the capital allocation logic that would fund R&D needed through and beyond 2027. 5
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF Scent outlines recovery drivers across Fine Fragrance, Consumer Fragrance, and Fragrance Ingredients, highlighting a 2H 2026 path of mid-single-digit growth for Fine Fragrance and low single-digit growth for Consumer Fragrance. The company emphasizes a stronger R&D pipeline and a go-to-market rebuild to support a 2027 plan, underscoring continued investment in higher-value ingredients and innovative delivery systems to sustain the cycle of growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent rebound is driven by operational gains, resilient Fragrance Ingredients, and a rebuilt R&D-and-go-to-market engine aimed at 2027 growth. In H2, Fine Fragrance eyes mid-single-digit gains with a Q3 soft patch and a stronger Q4, while Consumer Fragrance normalizes from Q2 highs as the R&D pipeline and customer partnerships drive market-share recovery.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a strong Fragrance Ingredients rebound, normalization in Fine Fragrance and Consumer Fragrance through the second half of 2026, and a strengthened R&D pipeline aimed at 2027. The company projects mid-single-digit growth for 2H 2026, with Q3 softness and Q4 strength for Fine Fragrance, while Consumer Fragrance stabilizes at low single-digit growth as R&D and go-to-market improvements take hold.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines the drivers behind Scent's rebound, highlighting stronger Fragrance Ingredients momentum, improved Consumer Fragrance trends, and a managed recovery in Fine Fragrance. It maps a softer Q3 with a stronger Q4 and ties the 2027 outlook to a rebuilt R&D capability, an expanded pipeline, and a redesigned go-to-market strategy aimed at restoring market share and product leadership.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi